公开(公告)号：US12012462B2

公开(公告)日：2024-06-18

申请号：US17046731

申请日：2019-04-10

Applicant: AMGEN INC. ,  KiTe Pharma, Inc.

Inventor： Michael John Giffin ,  Melissa Thomas ,  Christopher Murawsky ,  Ryan B. Case ,  Lawren Wu ,  Jed J. Wiltzius ,  Ruben Alvarez Rodriguez ,  Jun Feng

IPC: C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C12N15/86

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70521 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C12N2740/15041

Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.

公开(公告)号：US12012449B2

公开(公告)日：2024-06-18

申请号：US17525421

申请日：2021-11-12

Applicant: AMGEN INC.

Inventor： Jennifer E. Towne ,  Janet D. Cheng ,  Jason C. O'Neill ,  Yu Zhang ,  Yu Sun ,  Heather Cerne ,  Derek E. Piper ,  Randal R. Ketchem

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/24 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K39/395 ,  A61K47/6845 ,  C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.

公开(公告)号：US20240190951A1

公开(公告)日：2024-06-13

申请号：US18287593

申请日：2022-04-22

Applicant: AMGEN INC.

Inventor： Hao Zhang ,  Alla Polozova ,  Kelly Fitzpatrick ,  Kristin Abrams ,  Dong Xiang ,  Marisa K. Joubert

IPC: C07K16/24 ,  A61K39/00 ,  G01N33/68

CPC classification number: C07K16/244 ,  G01N33/6845 ,  G01N33/6854 ,  A61K39/00 ,  C07K2317/21 ,  C07K2317/41 ,  G01N2500/10

Abstract: The present application relates, in general, to compositions comprising anti-TSLP antibody tezepelumab and derivatives thereof having antibody quality attributes.

公开(公告)号：US20240182477A1

公开(公告)日：2024-06-06

申请号：US18472147

申请日：2023-09-21

Applicant: AMGEN INC. ,  VIGIL NEUROSCIENCE, INC.

Inventor： Lara C. CZABANIUK ,  Timothy HOPPER ,  Jonathan B. HOUZE ,  Jane PANTELEEV ,  Gwenaella RESCOURIO ,  Vincent SANTORA ,  Haoxuan WANG ,  Ryan D. WHITE ,  Alice R. WONG ,  Yongwei WU ,  Maxence BOS ,  John MANCUSO ,  Ivan FRANZONI

IPC: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04 ,  C07D475/00

CPC classification number: C07D487/04 ,  A61P25/28 ,  C07D413/14 ,  C07D471/04 ,  C07D475/00

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).




This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

公开(公告)号：US12000915B2

公开(公告)日：2024-06-04

申请号：US17766055

申请日：2020-10-02

Applicant: AMGEN INC.

Inventor： Marc A. Caporini ,  Ron C. Kelly ,  Mariana De Maillé

IPC: G01R33/44 ,  G01N24/08

CPC classification number: G01R33/448 ,  G01N24/08

Abstract: Disclosed herein is a method of conducting direct detection 1H solid state NMR (“ssNMR”) on a macromolecule-containing solid state formulation. The method includes conducting a 1H spin-lattice relaxation time (“T1”) experiment on the solid state formulation at various temperatures to generate a T1 value at each temperature, converting the T1 values to 1H spin-lattice relaxation rate (“R1”), and plotting R1 versus temperature to generate a relaxation rate curve for the solid state formulation. The relaxation rate curve can be analyzed to determine the molecular mobility of the macromolecule in the solid state formulation, the degree of aggregation in the solid state formulation, and/or the stability of the solid state formulation.

公开(公告)号：US20240174745A1

公开(公告)日：2024-05-30

申请号：US18316739

申请日：2023-05-12

Applicant: AMGEN RESEARCH (MUNICH) GMBH ,  AMGEN INC.

Inventor： Christoph Dahlhoff ,  Claudia Blümel ,  Johannes Brozy ,  Tobias Raum ,  Elisabeth Nahrwold ,  Tara Arvedson ,  Irwin Chen ,  Sandra Ross ,  Julie Bailis

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

公开(公告)号：US20240165338A1

公开(公告)日：2024-05-23

申请号：US18550647

申请日：2022-03-03

Applicant: AMGEN INC.

Inventor： Jan Mikael JENSEN ,  Lars EILERTSEN

IPC: A61M5/315 ,  A61M5/20 ,  A61M5/31

CPC classification number: A61M5/31515 ,  A61M5/20 ,  A61M2005/2086 ,  A61M2005/3143 ,  A61M2205/02

Abstract: A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a barrel, a stopper and a delivery member, the stopper movably positioned within the barrel and the delivery member positioned at a distal end of the barrel and having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to engage the stopper and expel a drug from the drug storage container through the delivery member, the plunger including a body portion and a shock absorbing portion. The device may further include a plunger biasing member coupled with the plunger and configured to urge the plunger toward the distal end of the drug storage container.

公开(公告)号：US20240150448A1

公开(公告)日：2024-05-09

申请号：US18545688

申请日：2023-12-19

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Irwin CHEN ,  Su CHONG ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Derek E. PIPER ,  Kenneth William WALKER ,  Zhulun WANG ,  Cen XU

IPC: C07K16/18 ,  A61K38/22 ,  A61P25/06 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K2039/545 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US11976103B2

公开(公告)日：2024-05-07

申请号：US17065395

申请日：2020-10-07

Applicant: Amgen Inc.

Inventor： Eric Alan Butz ,  Christy Ann Thomson ,  Marc Alain Gavin ,  Ian Nevin Foltz ,  Dong Xia ,  Dina N. Alcorn ,  Randal Robert Ketchem ,  Ai Ching Lim ,  Kathy Manchulenko ,  Laura Sekirov ,  Kelly Ann Berry ,  Cyr Clovis Chua De Imus ,  Neeraj Jagdish Agrawal ,  Gunasekaran Kannan ,  Li Li

IPC: A61K38/20 ,  A61P37/00 ,  C07K14/55 ,  C07K16/24

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61P37/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US11976102B2

公开(公告)日：2024-05-07

申请号：US17063566

申请日：2020-10-05

Applicant: Amgen Inc.

Inventor： Marc Alain Gavin ,  Gunasekaran Kannan ,  Li Li ,  Joshua Thomas Pearson ,  Margaret Karow

IPC: A61K38/00 ,  C07K14/55 ,  C07K16/00

CPC classification number: C07K14/55 ,  C07K16/00 ,  A61K38/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.